Several studies have demonstrated that TPX2 is overexpressed in esophageal squamous cell carcinoma, breast, colon and prostate cancer (Hsu et al., 2014; Wei et al., 2013; Yang et al., 2015; Zou et al., 2018). Here, TPX2 is linked to prostate cancer.